

**NEW HMBD-002 PRECLINICAL DATA TO BE PRESENTED AT  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)  
ANNUAL MEETING**

**Melbourne, Australia – 31 March 2026:** Percheron Therapeutics Limited (ASX: PER) ('the Company'), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to advise that new preclinical data for its investigational cancer therapy, HMBD-002, has been accepted for presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, IL, from 29 May – 2 June 2026.

The ASCO Annual Meeting is widely regarded as the foremost annual conference for practicing oncologists and clinical researchers, as well as a key event for investors and pharmaceutical companies. It typically attracts up to 50,000 attendees from over 100 countries and territories. In 2025, more than 7,500 abstracts were submitted to ASCO for consideration, with only a minority of those being selected for oral or poster presentations.

An abstract outlining the data was submitted to ASCO by a research team at QIMR Berghofer in Brisbane, Queensland. QIMR Berghofer is one of the leading independent medical research institutes in Australia, with a focus on cancer, infectious disease, population health and brain and mental health. It is home to nearly 1,000 scientists, students, visiting researchers and professional staff across a wide range of disciplines, and houses more than 60 research groups and laboratories.

The QIMR Berghofer abstract is the culmination of an ongoing research collaboration between Percheron and QIMR Berghofer to further explore the role of VISTA in several types of cancer, and to identify potential biomarkers that may be used in future clinical trials. The project has been led by Professor Sudha Rao, a leading expert on the use of immunotherapy in cancer. The Company looks forward to sharing full results at the time of the conference, in accordance with ASCO's embargo policies.

~ ENDS ~

For personal use only

---

### **About Percheron Therapeutics Limited**

Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated, and Percheron aims to commence further clinical trials in CY2026.

For more information, please contact [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorized for release to the Australian Securities Exchange  
by the Board of Directors.*

---